Chronic lymphocytic leukemia is the most common leukemia affecting mainly elderly individuals and follows an extremely variable course, with survival ranging from months to decades. Several characteristics of CLL facilitate basic and translational research including the high population prevalence, the easily obtainable malignant cells through venous phlebotomy, the asymptomatic phase in most patients that allows for longitudinal evaluation, and the relatively long disease-specific survival. Consensus guidelines for treatment of patients with CLL have been proposed by the ESMO Clinical Practice Guidelines, and recently recommended that the current use of prognostic tools for patients with newly diagnosed CLL should include staging (Rai or Binet), lymphocyte doubling time (LDT), Beta-2 microglobulin (β2M), CD38 and ZAP-70 markers, CLL-relevant fluorescence in situ hybridization (FISH) panel, and, if available, IgVH gene mutation status.
1) Dr. Waiel Mohmed Abdo Al-Kahiry. Faculty of Medicine, Aden University - Yemen. M.D. PhD Clinical Hematopathology.2 Dr. Hadeel Said Tawfik Abdelsalam. Pharos University in Alexandria - Egypt. M.D. PhD Clinical Hematopathology.3 Dr. Enas Ali Mohammed Dammag. Faculty of Medicine, Taiz University - Yemen. MD. PhD in Clinical Hematology.
Number of Pages:
LAP LAMBERT Academic Publishing
CLL, Chronic, lymphocytes, Leukemia, diagnosis, Treatment
MEDICAL / General